Hepatitis C virus (HCV) infection is a major problem worldwide, with 230 million reported cases, including 2.7 to 3.9 million cases (1.0%–1.5%) in the United States.1 The prevalence rates for HCV infection in patients with cancer range from 1.5% to 32%.2 Although HCV infection in this patient population is common, little is known about its management, and many oncologists remain unaware of current treatment options. Education of medical staff and the coordination of different specialties are essential to provide the appropriate patient stratification and best therapeutic approach to treating HCV infection in patients with cancer in the context of multiple comorbidities. Therefore, this special population of patients needs guided treatment and constant supervision. This commentary highlights the importance of treating HCV infection in patients with cancer and describes the educational experience with a transdisciplinary approach to treatment gained at our HCV infection clinic, the first clinic in the United States devoted to managing this infection in patients with cancer.3
(This commentary was presented in part at ID Week 2015, October 7–11, 2015, San Diego, California.)
The authors thank Don Norwood for editorial assistance.
TorresHAMahalePBlechaczB. Effect of hepatitis C virus infection in patients with cancer: addressing a neglected populationJ Natl Compr Canc Netw2015;13:41–50.
TorresHAAdachiJARoachLR. Hepatitis C clinic operated by infectious disease specialists at a comprehensive cancer center: help is on the way. Clin Infect Dis2012;54:740–742.
TorresHAKasebAMahaleP. Telaprevir-containing regimen for treatment of hepatitis C virus infection in patients with hepatocellular carcinoma awaiting liver transplantation: a case series. J Hepatocellular Carcinoma2014;1:109–114.
MahalePKontoyiannisDPChemalyRF. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol2012;57:1177–1185.
Peveling-OberhagJArcainiLHansmannMLZeuzemS. Hepatitis C-associated B-cell non-Hodgkin lymphomas: epidemiology, molecular signature and clinical management. J Hepatol2013;59:169–177.
ArcainiLVallisaDRattottiS. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. Ann Oncol2014;25:1404–1410.
KyvernitakisAMahalePPopatUR. Hepatitis C virus infection in patients undergoing hematopoietic cell transplantation in the era of direct-acting antiviral agents. Biol Blood Marrow Transplant2016;22:717–722.
KlingemannHGGriggAPWilkie-BoydK. Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse. Blood1991;78:3306–3311.
TorresHAMcDonaldGB. How we treat hepatitis C virus infection in patients with hematologic malignancies[published online ahead of print]. Bloodpii: blood-2016-05-718643.
TorresHAChongPPDe LimaM. Hepatitis C virus infection among hematopoietic cell transplant donors and recipients: American Society for Blood and Marrow Transplantation Task Force Recommendations. Biol Blood Marrow Transplant2015;21:1870–1882.
AroraSThorntonKMurataG. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med2011;364:2199–2207.